The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

Table 3 Correlations and associations between the MBDA score and radiographic progression or bone turnover markers

Measure	Time point or period for comparison with MBDA score	Number of available samples	r	p value	β (95% CI)¹	p value
∆SHS (baseline-12 months)²	BL	11	0.19	0.57	0.34 (−0.33–1.01)	0.23
	6 M	11	0.18	0.60	0.18 (−0.72–1.08)	0.62
	∆	11	0.19	0.57	−0.38 (−1.35–0.60)	0.34
Bone turnover markers³
βCTX	∆	23	0.22	0.31	1.10 (−6.79–8.99)	0.77
P1NP	∆	23	−0.14	0.54	−0.31 (−2.05–1.42)	0.70
BAP	∆	23	−0.01	0.98	−0.01 (− 0.17–0.15)	0.88
TRAP5b	∆	23	−0.20	0.37	0.00 (−0.03–0.03)	0.99
DKK1	∆	23	0.27	0.22	0.15 (−0.40–0.69)	0.57
Sclerostin	∆	23	0.11	0.63	0.10 (−0.37–0.56)	0.66

SHS Sharp/van der Heijde score, βCTX beta-isomerised carboxy terminal telopeptide of type I collagen, P1NP procollagen type 1 amino-terminal propeptide, TRAP5b tartrate-resistant acid phosphatase isoenzyme 5b, DKK1 Dickkopf-1, BAP bone-specific alkaline phosphatase, MBDA multi-biomarker disease activity, BL MBDA score at baseline, 6 M MBDA score at month 6, ∆ change (for SHS: ∆MBDA score from baseline to month 6 and ∆SHS from baseline to month 12; for bone turnover markers: both ∆ from baseline to month 6), r Spearman’s rank correlation, CI confidence interval
¹β: regression coefficient from multivariable linear regression analysis, after adjustment by age, gender and/or menopausal status, smoking status, RF status, and ACPA status
²UMC Utrecht cohort only
³HORUS cohort only

ISSN: 1478-6362